The following full text is a publisher’s version.

For additional information about this publication click this link.
http://hdl.handle.net/2066/165679

Please be advised that this information was generated on 2020-03-13 and may be subject to change.
Innate immune cell activation and epigenetic remodeling in symptomatic and asymptomatic atherosclerosis in humans in vivo

Siroon Bekkering a,1, Inge van den Munckhof d, Tim Nielen b, Evert Lamfers b, Charles Dinarello a, c, Joost Rutten a, Jacqueline de Graaf a, Leo A.B. Joosten a, Mihai G. Netea a, Marc E.R. Gomes b, Niels P. Riksen a, 1

a Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
b Department of Cardiology, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands
c University of Colorado Denver, Aurora, CO 80045, USA

Article info
Article history:
Received 9 July 2016
Received in revised form 29 September 2016
Accepted 11 October 2016
Available online 12 October 2016

Keywords:
Atherosclerosis
Monocytes
Inflammation
Metabolism
Epigenetics

Abstract
Background and aims: We have recently reported that monocytes can undergo functional and transcriptional reprogramming towards a long-term pro-inflammatory phenotype after brief in vitro exposure to atherogenic stimuli such as oxidized LDL. This process is termed ‘trained immunity’, and is mediated by epigenetic remodeling and a metabolic switch towards increased aerobic glycolysis. We hypothesize that trained immunity contributes to atherogenesis. Therefore, we investigated the inflammatory phenotype and epigenetic remodeling of monocytes from patients with and without established atherosclerosis.

Methods: Monocytes were isolated from 20 patients with severe symptomatic coronary atherosclerosis (total plaque score > 4 on coronary computed tomography angiography) and 17 patients with asymptomatic carotid atherosclerosis and matched controls for both groups. Ex vivo stimulation, RNA analysis and chromatin immunoprecipitation were performed.

Results: Monocytes from patients with symptomatic atherosclerosis have a higher production of pro-inflammatory cytokines upon LPS stimulation than healthy controls (TNF-α 499 ± 102 vs. 267 ± 45 pg/ml, p = 0.01). This was associated with lower histone 3 lysine 4 trimethylation (H3K4me3) (19% vs. 33%, p = 0.002), and lower H3K27me3 (0.005% vs. 0.8%, p < 0.0001) on the TNF-α promoter. Furthermore, relative mRNA expression of the glycolytic rate limiting enzymes hexokinase 2 and 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 was higher in patients (0.7 ± 0.2 vs. 0.3 ± 0.1 resp. 1.7 ± 0.2 vs. 1.0 ± 0.1, p = 0.007 resp. 0.003) compared to control individuals. Interestingly, this pro-inflammatory phenotype was only present in patients with symptomatic atherosclerosis, and not in patients with asymptomatic carotid atherosclerosis.

Conclusions: Circulating monocytes of patients with symptomatic, but not asymptomatic, atherosclerosis have a pro-inflammatory phenotype and increased expression of glycolytic enzymes, associated with epigenetic remodeling at the level of histone methylation.

© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

1. Introduction

Cardiovascular diseases (CVD) are the leading cause of death worldwide, projected to cause 30 million deaths per year in 2030 [1]. The main underlying pathological process of CVD is atherosclerosis, a chronic low-grade inflammatory disorder of the arterial wall. Macrophages are the most abundant cells found in plaques and play central roles in the various stages of atherosclerosis [2]. Plaque macrophages are both derived from circulating monocytes that bind to activated endothelial cells and enter the intimal layer as well as from local proliferating plaque macrophages [3]. The mechanism that explains the persistent non-resolving inflammation within atherosclerotic plaques remains to be elucidated.

We recently proposed that trained immunity contributes to the...
persistent vascular inflammation that characterizes atherosclerotic plaques [4]. Trained immunity denotes the process through which innate immune cells can adopt a long-term pro-inflammatory phenotype after brief exposure to certain pathogen- and danger-associated molecular patterns, such as oxidized low-density lipoprotein (oxLDL) particles [5]. Brief in vitro exposure of human monocytes to oxLDL induces a long-lasting pro-inflammatory macrophage phenotype that is characterized by increased pro-atherogenic cytokine and chemokine production and increased foam cell formation. The key mechanisms underlying this phenotype are epigenetic reprogramming at the level of histone methylation and a shift in the intracellular metabolism from oxidative phosphorylation towards an increased aerobic glycolysis (i.e. the Warburg effect) [6].

To test the hypothesis that trained immunity contributes to the development of atherosclerosis, we now performed a first proof-of-concept study in patients with established atherosclerosis. We aimed to investigate whether circulating monocytes of patients with atherosclerosis have a pro-inflammatory phenotype, and whether this is associated with epigenetic marks and change in metabolism that are characteristic of trained immune cells. To explore whether the role of trained immunity differs in the various stages of atherosclerosis, we studied monocytes from patients with symptomatic coronary atherosclerosis and subjects with asymptomatic carotid atherosclerosis.

2. Materials and methods

Expanded Materials and methods are available in the Supplementary materials.

2.1. Study participants

Patients with symptomatic coronary atherosclerosis were selected from patients who had been referred to the cardiac emergency ward of the Canisius Wilhelmina Hospital in Nijmegen, from October 2013 to March 2014, because of chest pain, and who were evaluated with coronary computed tomography angiography (CCTA). We selected twenty patients with a total plaque score (TPS) > 4 (patients) and twenty control patients with a TPS = 0 (controls). Patients and controls were matched for age, gender and body mass index (BMI). Exclusion criteria were diabetes, rheumatoid arthritis, or other autoimmune diseases and signs/symptoms of acute infection.

Patients with asymptomatic carotid atherosclerosis were selected using carotid ultrasound from the participants of the population-based IN CONTROL study, from October 2013 to July 2015. A total of 39 asymptomatic subjects were included. Exclusion criteria for this study were a recent cardiovascular event, history of bariatric surgery or bowel resection, inflammatory bowel disease, renal dysfunction, increased bleeding tendency, use of oral subcutaneous anti-coagulant therapy, and use of thrombocyte aggregation inhibitors other than acetylsalicylic acid.

All laboratory analyses were performed blinded for group allocation. The study protocol was approved by the Institutional Review Board Arnhem/Nijmegen, The Netherlands, and prospectively registered at ClinicalTrials.gov (number NCT02393768).

2.2. Evaluation of atherosclerotic burden

Atherosclerotic burden was assessed as described in the

Supplementary materials.

2.3. Blood sampling, isolation and stimulation of monocytes

EDTA plasma was obtained by venous blood sampling and was stored using standardized protocols. Plasma total cholesterol, HDL-c and LDL-c levels were analyzed using commercially available enzymatic methods. PAXgene tubes (Preanalytix, GmbH, Switzerland) were incubated for at least 2 h at room temperature before storage at −20 °C until RNA isolation.

Human peripheral blood mononuclear cells (PBMCs) were isolated from EDTA blood using Ficoll-Paque density gradient centrifugation (GE Healthcare, UK). Monocytes were isolated by magnetic activated cell sorting (MACS) using CD14-coated MicroBeads according to manufacturer’s instructions (MACS, Miltenyi Biotec, Leiden, The Netherlands). Monocytes were diluted to 1 × 10⁶/ml in RPMI 1640 Dutch-modified culture medium (Life Technologies/Invitrogen, Breda, The Netherlands) supplemented with 10 mM glucose (Invitrogen), 10 μg/ml gentamicin (Centrafora), 10 mM pyruvate (Invitrogen). A total of 5 × 10⁵ monocytes were seeded per well on flat-bottom 96-well plates (Corning, New York, USA) and stimulated for 24 h with RPMI only as a negative control, 10 ng/ml LPS (Sigma-Aldrich, St. Louis, MO; from E. coli serotype 055:B5), further purified as described [7] or 10 μg/ml Pam3Cys (EMC microcollections, Tübingen, Germany; L2000). After 24 h, plates were centrifuged and supernatants were stored at −20 °C until cytokine assessment.

2.4. Cytokine measurements

Cytokine production was determined in supernatants as described in Supplementary materials.

2.5. RNA isolation from PAXgenes

Total RNA purification was performed as described in Supplementary materials.

2.6. Chromatin immunoprecipitation

For the assessment of histone methylation, chromatin immunoprecipitation (ChIP) was performed as described previously [8]. In short, monocytes were cross-linked in methanol free 1% formaldehyde (28908, Thermo Scientific), followed by sonication to shear-DNA and immunoprecipitation using antibodies against H3K4me3, H3K27me3 and H3K9me3 (Diagenode, Seraing, Belgium). ChIPed DNA was processed further for qPCR analysis. Primers used in the reaction are listed in Supplementary Table 2. Samples were analyzed following a comparative Ct method, myoglobin was used as a negative control for H3K4me3, GAPDH for H3K9me3 and ELF4A2 for H3K27me3. H2B was used as a positive control for H3K4me3, ZNF UTR for H3K9me3 and MYT1 for H3K27me3 according to the manufacturer’s instructions.

2.7. Statistics

Data are presented as mean (standard deviation) for continuous variables and as number (percentage) for categorical variables. To examine the difference in clinical characteristics between the different patient groups, we performed unpaired student t-tests or Mann-Whitney U tests for normal and non-normal distributed variables, respectively. Ex vivo monocyte experiments were analyzed using the Mann-Whitney U test. In vitro experiments were analyzed using the Wilcoxon signed rank test. A two-sided p-value below 0.05 was considered statistically significant. All data were
analyzed using Prism version 5.0 (GraphPad software, La Jolla, California) or SPSS version 21.0 (SPSS Inc., Chicago, Illinois).

3. Results

3.1. Baseline characteristics

Baseline characteristics of patients with symptomatic subjects with asymptomatic atherosclerosis, and controls for both groups without atherosclerosis are listed in Table 1. The average total plaque score (TPS) derived from the Coronary Computed Tomography Angiography (CCTA) was 6.3 in patients (A), indicating severe coronary atherosclerosis, and 0 in controls (B), indicating no coronary atherosclerosis (Table 1). Subjects with asymptomatic coronary atherosclerosis showed no significant differences between group A and B in blood pressure, total cholesterol, lipoprotein(a), LDL cholesterol, glucose or plasma creatinine. High density lipoprotein (HDL) cholesterol was slightly lower in patients with coronary artery disease (CAD) (1.45 mmol/L vs. 1.26 mmol/L, p = 0.04). Statin use was higher in patients than controls (75% vs. 15%, p < 0.001).

Similarly, there were no significant differences between subjects with (C) and without (D) asymptomatic carotid plaques, besides the presence of plaques measured by carotid ultrasound.

3.2. Increased systemic inflammation in patients with symptomatic atherosclerosis

We measured baseline circulating high-sensitive C-reactive protein (hsCRP), cytokines and chemokines in patients with symptomatic CAD and controls. Plasma samples of patients with symptomatic CAD did not show significantly higher concentrations of IL-6 and TNFα (Fig. 1A), although this may be due to the lack of power. There was no difference in MCP-1 concentration. hsCRP was significantly higher in patients compared to controls (p < 0.01). Subjects with asymptomatic carotid atherosclerosis showed no differences in pro-inflammatory cytokines and hsCRP plasma concentrations (Fig. 1B) compared to controls.

3.3. Increased cytokine and chemokine production by monocytes from subjects with symptomatic, but not asymptomatic atherosclerosis

After overnight stimulation with the Toll-like receptor (TLR) 4 ligand lipopolysaccharide (LPS), monocytes isolated from patients with symptomatic CAD showed an increased production of interleukin-6 (IL-6), tumor necrosis factor-α (TNFα), IL-1β, IL-8 and monocyte chemotracting protein-1 (MCP-1; Fig. 2A) compared to controls. Similar results were observed upon stimulation with the TLR2 ligand Pam3Cys (Supplementary Fig. 1). No differences were observed in production of the anti-inflammatory cytokine IL-10, since levels were below detection level (data not shown).

In contrast, monocytes from subjects with asymptomatic carotid atherosclerosis did not show increased production of IL-6, TNFα, IL-1β, IL-8 and MCP-1, upon TLR4 stimulation, compared to control subjects without carotid atherosclerosis (Fig. 2B). Similar results were obtained after stimulation of leukocytes by the TLR2 ligand Pam3Cys (Supplementary Fig. 2).

3.4. Circulating cells of patients with symptomatic CAD have a pro-inflammatory phenotype associated with metabolic reprogramming

3.4.1. Increased pro-inflammatory cytokine expression

To further characterize the pro-inflammatory phenotype in patients with symptomatic CAD, we measured baseline RNA expression of pro-inflammatory cytokines and other inflammatory genes. Baseline expression of TNFα, IL-1β and IL-1RA was significantly higher in patients with symptomatic CAD compared to controls (Fig. 3A and Supplementary Fig. 3B), expression of MCP-1, IL-8, IL-6 as well as expression of HIF-1α, c-MYC and STAT3 showed no difference.

3.4.2. Increased expression of glycolytic enzymes

We have recently reported that the persistent pro-inflammatory phenotype of monocytes after induction of trained immunity by β-glucan is critically dependent on epigenetic reprogramming and a metabolic shift towards increased aerobic glycolysis [6]. We measured mRNA expression of hexokinase 2 (HK2) and 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3),

Table 1

Baseline characteristics of the participants.

| Characteristics                  | (A) Symptomatic coronary atherosclerosis (n = 20) | (B) Controls (n = 20) | p value | (C) Asymptomatic carotid atherosclerosis (n = 17) | (D) Controls (n = 22) | p value |
|----------------------------------|-------------------------------------------------|-----------------------|---------|-----------------------------------------------|-----------------------|---------|
| Age, y                           | 52 ± 11                                         | 53 ± 12               | 0.78    | 67 ± 6                                        | 66 ± 4                | 0.43    |
| Gender, % male (n)               | 75 (15)                                         | 50 (10)               | 0.19    | 29 (5)                                        | 45 (10)               | 0.32    |
| BMI (kg/m²)                      | 28.6 ± 4.1                                      | 26.5 ± 3.5            | 0.08    | 29.6 ± 2.3                                    | 31.1 ± 4.7            | 0.24    |
| SBP (mmHg)                       | 145 ± 21                                        | 142 ± 17              | 0.63    | 130 ± 10                                      | 130 ± 14              | 0.95    |
| DBP (mmHg)                       | 80 ± 14                                         | 83 ± 11               | 0.54    | 79 ± 6                                        | 82 ± 9                | 0.22    |
| Family history, % yes (n)        | 60 (12)                                         | 35 (7)                | 0.21    | 47 (8)                                        | 37 (8)                | 0.24    |
| Smoking, % active (n)            | 20 (4)                                          | 20 (4)                | —       | 6 (1)                                         | 9 (2)                 | 0.72    |
| Smoking (pack years)             | 18 ± 12                                         | 22 ± 20               | 0.47    | —                                             | —                     |         |
| Statin use, % yes (n)            | 75 (15)                                         | 15 (3)                | 0.00    | 0 (0)                                         | 0 (0)                 | 1       |
| TChol, mmol/L                    | 5.1 ± 1.2                                       | 4.9 ± 1.7             | 0.92    | 6.2 ± 0.9                                     | 6.0 ± 1.07            | 0.55    |
| LDLc, mmol/L                     | 3.0 ± 1.0                                       | 2.9 ± 1.2             | 0.93    | 4.12 ± 0.8                                    | 4.09 ± 0.9            | 0.47    |
| HDLc, mmol/L                     | 1.3 ± 0.3                                       | 1.5 ± 0.6             | 0.04    | 1.4 ± 0.3                                     | 1.4 ± 0.2             | 0.70    |
| Glucose, mmol/L                  | 6.3 ± 1.8                                       | 5.8 ± 1.6             | 0.37    | 5.4 ± 0.8                                     | 5.3 ± 0.7             | 0.71    |
| Creatinine μmol/L                | 80.3 ± 16.5                                     | 80.3 ± 16.5           | 0.19    | 82.2 ± 12.5                                   | 80.1 ± 17.2           | 0.67    |
| % Monocytes                      | 12.3 ± 3.5                                      | 13.5 ± 4.3            | 0.34    | 8.6 ± 1.3                                     | 8.9 ± 2.1             | 0.65    |
| Total Plaque Score (TPS)         | 6.3 [4–12]                                      | 0                     | <0.0001 | —                                             | 0 (22)                | <0.0001 |
| Plaque on carotid ultrasound % (n) | –                                               | –                     | –       | 100 (17)                                      | 0 (22)                | <0.0001 |

Data are presented as mean ± SD or n (%).

BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; TChol, total cholesterol; LDLc, low density lipoprotein cholesterol; HDLc, high density lipoprotein cholesterol; Lp(a), lipoprotein (a).
the two rate-limiting enzymes in the glycolysis pathway, as well as the expression of other important metabolic enzymes in patients with symptomatic CAD and control patients. Patients with symptomatic CAD showed a higher baseline expression of HK2, PFKFB3, pyruvate kinase 1 (PKM1), argininosuccinate lyase (ASL), malate dehydrogenase 1 (MDH1), pyruvate dehydrogenase alpha 1 (PDHA1) and transaldolase 1 (TALDO1) (Fig. 3A and Supplementary Fig. 3B). This is consistent with an upregulation of genes of the glycolytic pathway, but also enzymes in the pentose-phosphate pathway and Krebs cycle (Fig. 3B). Expression of HK2 and IL-1β (R = 0.41, p = 0.01), PFKFB3 and TNFα (R = 0.45, p = 0.006) and PFKFB3 and IL-1β (R = 0.78, p < 0.001) are significantly correlated, corroborating an association between upregulated glycolysis and an increased baseline inflammatory state (Supplementary Fig. 3A).

3.5. Increased cytokine production is associated with lower repressive epigenetic marks in patients with symptomatic CAD

Trained immunity is mediated by epigenetic reprogramming at the level of histone methylation [9]. Previously, we showed that increased cytokine production after brief exposure to oxLDL or β-glucan was associated with an enrichment of the activating histone mark H3K4me3, and training was prevented by nonselective inhibitors of methyltransferases [5,10]. Since patients with symptomatic CAD have elevated pro-inflammatory cytokines and the level of histone methylation [9]. Previously, we showed that circulating monocytes of patients with established atherosclerosis have a pro-inflammatory phenotype, associated with epigenetic remodeling at the level of histone methylation and increased expression of rate limiting enzymes of the glycolysis pathway and the pentose phosphate pathway. Interestingly, this pro-inflammatory phenotype was present only in patients with severe symptomatic coronary atherosclerosis, and not in patients with mild asymptomatic carotid atherosclerosis.

Fig. 1. Inflammatory markers in plasma. (A) IL-6, TNFα, MCP-1 and hsCRP were measured in EDTA plasma from patients with symptomatic CAD vs. matched controls. Baseline inflammation in patients with symptomatic CAD was increased compared to controls. (B) IL-6 and hsCRP were measured in plasma from patients with asymptomatic carotid atherosclerosis vs. matched controls. Asymptomatic carotid atherosclerosis subjects showed no increased baseline inflammation compared to controls.

the expression of important metabolic enzymes in patients with symptomatic CAD and control patients. Patients with symptomatic CAD showed a higher baseline expression of HK2, PFKFB3, pyruvate kinase 1 (PKM1), argininosuccinate lyase (ASL), malate dehydrogenase 1 (MDH1), pyruvate dehydrogenase alpha 1 (PDHA1) and transaldolase 1 (TALDO1) (Fig. 3A and Supplementary Fig. 3B). This is consistent with an upregulation of genes of the glycolytic pathway, but also enzymes in the pentose-phosphate pathway and Krebs cycle (Fig. 3B). Expression of HK2 and IL-1β (R = 0.41, p = 0.01), PFKFB3 and TNFα (R = 0.45, p = 0.006) and PFKFB3 and IL-1β (R = 0.78, p < 0.001) are significantly correlated, corroborating an association between upregulated glycolysis and an increased baseline inflammatory state (Supplementary Fig. 3A).

3.5. Increased cytokine production is associated with lower repressive epigenetic marks in patients with symptomatic CAD

Trained immunity is mediated by epigenetic reprogramming at the level of histone methylation [9]. Previously, we showed that increased cytokine production after brief exposure to oxLDL or β-glucan was associated with an enrichment of the activating histone mark H3K4me3, and training was prevented by nonselective inhibitors of methyltransferases [5,10]. Since patients with symptomatic CAD have elevated pro-inflammatory cytokines and the level of histone methylation [9]. Previously, we showed that circulating monocytes of patients with established atherosclerosis have a pro-inflammatory phenotype, associated with epigenetic remodeling at the level of histone methylation and increased expression of rate limiting enzymes of the glycolysis pathway and the pentose phosphate pathway. Interestingly, this pro-inflammatory phenotype was present only in patients with severe symptomatic coronary atherosclerosis, and not in patients with mild asymptomatic carotid atherosclerosis.

Fig. 1. Inflammatory markers in plasma. (A) IL-6, TNFα, MCP-1 and hsCRP were measured in EDTA plasma from patients with symptomatic CAD vs. matched controls. Baseline inflammation in patients with symptomatic CAD was increased compared to controls. (B) IL-6 and hsCRP were measured in plasma from patients with asymptomatic carotid atherosclerosis vs. matched controls. Asymptomatic carotid atherosclerosis subjects showed no increased baseline inflammation compared to controls.
The underlying molecular basis of trained immunity is only partially deciphered and comprises changes in chromatin organization and intracellular metabolism. In human monocytes trained with β-glucan, a shift from oxidative phosphorylation towards aerobic glycolysis through the AKT-mTOR-HIF-1α pathway was observed, accompanied by changes in histone marks such as H3K4me1, H3K4me3 and H3K27Ac. Both pathways are non-redundant, since pharmacological inhibitors of glycolysis, such as 2-deoxy-D-glucose and inhibitors of the mTOR pathway, such as metformin, as well as non-specific inhibitors of histone methyltransferases, prevented β-glucan-induced trained immunity [6,10].

Here we show that in patients with symptomatic CAD, monocytes display an increased pro-inflammatory cytokine response upon ex vivo TLR4/2 stimulation. Previously, ex vivo inflammatory responses in patients with and without atherosclerosis were studied mainly in whole blood or peripheral blood mononuclear cells (PBMCs) [14-16]. In addition, baseline expression of cytokines, baseline expression of the two rate-limiting glycolysis genes, as well as the expression of several other enzymes in glycolysis, pentose phosphate pathway and Krebs cycle were increased in whole blood. In this study, the pro-inflammatory phenotype was also associated with changes in the epigenetic landscape in the monocytes. First, we studied the level of H3K4me3, a long-term activating histone mark. In contrast to our in vitro observations, however, H3K4me3 occupancy on TNFα promoter was lower in patients with CAD. The accessibility of the chromatin is determined by activating epigenetic marks as well as repressive epigenetic marks. The repressive mark H3K27me3 importantly contributes to the LPS-induced pro-inflammatory cytokine production [12]. Previously, Wierda et al. used immunohistochemistry to show a...
reduction of global levels of H3K27me3 modification in vessels with advanced plaques, which was not accompanied by alterations in global levels of the corresponding histone methyltransferase EZH2 [17], corresponding to our current findings. Greissel et al. showed a significant reduction of repressive marks H3K9me2 and H3K27me2 with increasing plaque severity, in plaque macrophages [18]. Although measured in plaque macrophages and not in circulating cells, these studies indicate that repressive marks are strongly associated with the severity of atherosclerotic disease. In our study, we also determined H3K9me3 and H3K27me3 on the TNFα promoter. Although H3K9me3 was not significantly different between patients with and without atherosclerosis, H3K27me3 was much lower and correlated with cytokine RNA expression levels. Recently, Schmidt et al. studied the transcriptional regulator network of human inflammatory macrophages by histone marks. They showed that when promoter regions only have H3K4me3 marks, they are in an open chromatin state. When promoter regions are additionally trimethylated on H3K27me3, the promoter region is ‘poised’ and transcription is prevented [19]. Furthermore, Kruidenier et al. showed that H3K27 demethylation is a critical determinant for LPS induced TNFα production, and higher baseline levels of H3K27me3 can result in lower TNFα production [12].

Baseline RNA expression analysis showed increased expression of the rate-limiting enzymes of the glycolytic pathway as well as
other important rate-limiting metabolic enzymes in patients with severe atherosclerosis. Previously, we have shown that trained immunity depends on a metabolic shift, resulting in increased glycolysis [6,10]. An increase in gene expression of the two rate-limiting glycolytic genes is compatible with this metabolic shift that characterizes trained immunity [10]. The upregulation of other rate-limiting metabolic enzymes involved in the pentose phosphate pathway and Krebs cycle indicates a more general activation of intracellular metabolism, as shown in Fig. 4B. Recently, Tawakol et al. showed that in plaque macrophages there is a relationship between PFKFB3 expression and pro-inflammatory activation, via hypoxia-induced upregulation of macrophage glycolysis. The authors showed a linear relationship between macrophage energetics on the one hand and inflammatory activation on the other hand, regulated via PFKFB3 expression [20]. Furthermore, Shirai et al. showed that circulating monocytes and monocyte-derived macrophages from patients with established atherosclerosis have increased inflammation and glycolysis [21]. This study, however, differs markedly from our study, since these patients already suffered from an acute myocardial infarction, which in itself is a well-known trigger of innate immune activation [22]. In our study, all subjects with coronary atherosclerosis were free from previous cardiovascular events. Here we show, for the first time, that baseline gene expression of glycolysis and intracellular metabolism...
genes in circulating cells is also increased in event-free patients with established atherosclerosis, which is also associated with changes in the epigenetic landscape.

We propose that the pro-inflammatory phenotype of circulating monocytes in patients with severe coronary atherosclerosis reflects a trained immune phenotype, but we can only speculate about the stimulus that has instigated this immunological program. We have previously shown that several PAMPs and DAMPs can induce trained immunity, including Bacillus Calmette-Guérin, Candida albicans, β-glucan, and pro-atherogenic stimuli such as modified LDL and Lp(a) [5,8,9,23]. Our patients and controls did not show any differences in total cholesterol levels, LDL cholesterol or Lp(a), but the majority of the patients were being treated with statins. It is probable that before the initiation of statin treatment, LDL was higher in patients with CAD. Furthermore, the effects of statins on epigenetic modifications are still unknown. HDL cholesterol was lower in patients, but we do not yet know the effects of HDL cholesterol on trained immunity. Interestingly, the trained immune phenotype of circulation monocytes was only present in patients with severe symptomatic coronary atherosclerosis, and not in patients with asymptomatic carotid atherosclerosis, which was diagnosed by screening of healthy subjects. A potential explanation for this finding is that trained immunity contributes to the progression of complex atherosclerotic plaques and not to the initial formation of early lesions, which are observed in the majority of subjects. This finding is consistent with previous findings in patients with elevated levels of lipoprotein(a), which can also induce trained immunity in vitro [23]. Interestingly, most studies report that elevated lipoprotein (a) is not associated with early atherosclerotic lesions (e.g. carotid IMT) whereas elevated lipoprotein(a) is consistently associated with cardiovascular events, which mostly result from vulnerable atherosclerotic plaques [24–26]. Obviously, this finding requires confirmation in a larger cohort of patients.

Our study has several potential limitations. First of all, our results only indicate an association between atherosclerosis and trained immunity, and do not provide proof of causality. In theory, effects on the immune system could be caused by the atherosclerosis itself. Intervention studies in animal models of atherosclerosis will be required to provide final proof that trained immunity contributes to the development/progression of atherosclerosis. Secondly, the majority of patients with CAD used statins, in contrast to the control group. However, since statins are known to have potent anti-inflammatory effects [27], it is very unlikely that they have contributed to the pro-inflammatory monocyte phenotype, although they may have partially masked its full effects. Thirdly, it is important to realize that RNA expression was studied in whole blood using PAXgene tubes, to prevent changes in the RNA expression levels by the isolation of monocytes. However, it is likely that differences in RNA expression that we observed between patients with and without atherosclerosis are relevant for the monocyte fraction: first, we measured expression of various cytokines that are predominantly derived from monocytes, including TNF, IL1b, and IL6. Secondly, there is a strong correlation between the expression of enzymes of the glycolytic pathway (HK2/PFKFB3) and these cytokines, suggesting that this increased glycolysis is relevant for monocytes. Finally, in a previous study in patients with atherosclerosis, this increased expression of glycolytic enzymes was also observed in isolated monocytes after differentiation into M1 macrophages, compared to monocytes from patients without atherosclerosis [21].

Here we show that monocytes of patients with symptomatic CAD but not patients with asymptomatic carotid atherosclerosis have a pro-inflammatory phenotype, which is associated with metabolic reprogramming on the level of RNA expression towards increased glycolysis, and with epigenetic remodeling of pro-inflammatory genes. These findings suggest that trained immunity could play a role in the progression of mild and asymptomatic atherosclerotic plaques towards symptomatic disease.

Conflicts of interest

NPR served on a Scientific Advisory Board of AstraZeneca, which is unrelated to the current paper. NPR and MGN received non-restricted research grants from AstraZeneca, unrelated to the current paper.

Financial support

NPR is supported by a grant of the Netherlands Heart Foundation (#2012T051). NPR and MGN are supported by a Horizon2020 grant of the European Union (#667837). MGN is supported by an ERC Consolidator Grant (#310372). IvdM, JR and JdG are supported by a grant of the Netherlands Heart Foundation (CVON 2012-03 IN-CONTROL).

Author contributions

SB, MERN and NPR designed the study. IvdM, JR, JdG, TN and MERN included all the patients and controls, EIJ analyzed the atherosclerosis burden. SB performed all the blood isolation and analysis. CD supplied the materials for high sensitivity ELISA on plasma. SB and NPR wrote the article. LABJ, MGN, MERG, IvdM, JR and JdG revised the article.

Acknowledgements

We thank Heidi Lemmers, Helga Toenhake-Dijkstra, Kiki Schraa, Thijs Remijn, Charlotte van der Heijden and Sam Keating for their help with the experiments. We thank R&D systems for providing us the materials for using the Simple Plex system.

Appendix A. Supplementary data

Supplementary data related to this article can be found at http://dx.doi.org/10.1016/j.atherosclerosis.2016.10.019.

References

[1] A. Alwan, T. Armstrong, D. Bettcher, Global Status Report on Noncommunicable Diseases, World Health Organization, 2011.
[2] K.J. Moore, I. Tabas, Macrophages in the pathogenesis of atherosclerosis, Cell 145 (2011) 341–355.
[3] C.S. Robbins, et al., Local proliferation dominates lesional macrophage accumulation in atherosclerosis, Nat. Med. 19 (2013) 1166–1172.
[4] S. Bekkering, L.A.B. Joosten, J.W.M. van der Meer, M.G. Netea, N.P. Riksen, Trained innate immunity and atherosclerosis, Curr. Opin. Lipidol. 24 (2013) 487–492.
[5] S. Bekkering, et al., Oxidized low-density lipoprotein induces long-term proinflammatory cytokine production and foam cell formation via epigenetic reprogramming of monocytes, Arterioscler. Thromb. Vasc. Biol. 34 (2014) 1731–1738.
[6] S. Saeed, et al., Epigenetic programming of monocyte-to-macrophage differentiation and trained innate immunity, Science 345 (2014) (80–.) 1251086–1251086.
[7] M. Hirschfeld, Y. Ma, J.H. Weis, S.N. Vogel, J.J. Weis, Cutting edge: repurification of lipopolysaccharide eliminates signaling through both human and murine toll-like receptor 2, J. Immunol. 165 (2000) 618–622.
[8] J. Kleinnijenhuis, et al., Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes, Proc. Natl. Acad. Sci. U. S. A. 109 (2012) 17537–17542.

[9] J. Quintin, et al., Candida albicans infection affords protection against reinfection via functional reprogramming of monocytes, Cell Host Microbe 12 (2012) 223–232.

[10] S.-C. Cheng, et al., mTOR- and HIF-1α-mediated aerobic glycolysis as metabolic basis for trained immunity, Science 345 (2014) (80–) 1250684–1250684.

[11] J. Wang, et al., SKL-MB induces apoptosis through the AKT/mTOR signaling pathway in melanoma models and inhibits angiogenesis with decrease of ERK1/2 phosphorylation, J. Pharmacol. Sci. 126 (2014) 198–207.

[12] L. Kruidenier, et al., A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response, Nature 488 (2012) 404–408.

[13] J.D. Stender, C.K. Glass, Epigenomic control of the innate immune response, Curr. Opin. Pharmacol. 13 (2013) 582–587.

[14] P.L. van Haelst, et al., Circulating monocytes in patients with acute coronary syndromes lack sufficient interleukin-10 production after lipopolysaccharide stimulation, Clin. Exp. Immunol. 138 (2004) 364–368.

[15] N. de Bont, et al., LPS-induced cytokine production and expression of LPS-receptors by peripheral blood mononuclear cells of patients with familial hypercholesterolemia and the effect of HMG-CoA reductase inhibitors, Atherosclerosis 139 (1998) 147–152.

[16] A.L. Pasqui, et al., Pro-inflammatory/anti-inflammatory cytokine imbalance in acute coronary syndromes, Clin. Exp. Med. 6 (2006) 38–44.

[17] R. Wierda, et al., Global histone H3 lysine 27 triple methylation levels are reduced in vessels with advanced atherosclerotic plaques, Life Sci. 129 (2015) 3–9.

[18] A. Greisel, et al., Histone acetylation and methylation significantly change with severity of atherosclerosis in human carotid plaques, Cardiovasc Pathol. 25 (2016) 79–86.

[19] S.V. Schmidt, et al., The transcriptional regulator network of human inflammatory macrophages is defined by open chromatin, Cell Res. 26 (2016) 151–170.

[20] A. Tawakol, et al., HIF-1α and PFKFB3 mediate a tight relationship between proinflammatory activation and anaerobic metabolism in atherosclerotic macrophages, Arterioscler. Thromb. Vasc. Biol. 35 (2015) 1463–1471.

[21] T. Shirai, et al., The glycolytic enzyme PKM2 bridges metabolic and inflammatory dysfunction in coronary artery disease, J. Exp. Med. 213 (2016) 337–354.

[22] P. Dutta, et al., Myocardial infarction accelerates atherosclerosis, Nature 487 (2012) 325–329.

[23] F.M. van der Valk, et al., Oxidized phospholipids on lipoprotein(a) elicit arterial wall inflammation and an inflammatory monocyte response in humans, Circulation 134 (2016) 611–624.

[24] P. Calmarza, J.M. Trejo, C. Lapresta, P. Lopez, Relationship between lipoprotein(a) concentrations and intima-media thickness: a healthy population study, Eur. J. Prev. Cardiol. 19 (2012) 1290–1295.

[25] M. Kivimäki, et al., Conventional and Mendelian randomization analyses suggest no association between lipoprotein(a) and early atherosclerosis: the Young Finns Study, Int. J. Epidemiol. 40 (2011) 470–478.

[26] S. Bos, et al., Lipoprotein (a) levels are not associated with carotid plaques and carotid intima media thickness in statin-treated patients with familial hypercholesterolemia, Atherosclerosis 242 (2015) 226–229.

[27] C. Rothe, et al., A more mature phenotype of blood mononuclear phagocytes is induced by fluorastatin treatment in hypercholesterolemic patients with coronary heart disease, Atherosclerosis 144 (1999) 251–261.